All News

From New Jersey Governor Phil Murphy announcing he will undergo surgery to remove a potentially cancerous tumor on his kidney to an NHL team granting a 15-year-old fan with cancer the ultimate wish, here’s what is making headlines in the cancer space this week.

Here is a list of the recent trial initiations that occurred within the cancer space in February.

Patients with relapsed/refractory mantle cell lymphoma saw more favorable responses with the BTK inhibitor Imbruvica (ibrutinib) than with chemotherapy, according to nearly a decade of data.

One survivor offers her suggestions to handle chemo brain as she copes with her almost-10-year-old chemo brain.

Patients with a compromised immune system are more susceptible to the coronavirus, including those with cancer. Here are four key things patients with cancer should know about the novel coronavirus.

Don't be intimidated by the science presented at poster sessions at conferences. They can connect people living with cancer and cancer researchers in a way that helps both the patient and the researcher.

The Food and Drug Administration has granted approval to the combination of Nerlynx and Xeloda for the treatment of patients with advanced or metastatic HER2-positive breast cancer.

Men who identify as gay or bisexual report having more skin cancers than those who identify as heterosexual. More frequent use of indoor tanning could be a cause, but researchers want to find out for sure.

One survivor shares three things that helped her find a sense of control in the chaos that a cancer diagnosis can bring.

51% of Americans 50-54 have not been screened for colorectal cancer. We know screening saves lives, here's why.

Stupid Cancer is excited to bring CancerCon® to Seattle, WA this April 16 - 19, 2020.

Sexual and gender minorities are not receiving the same standard of clinical care as other patients with cancer.

This article outlines three areas where LGBTQ patients and their caregivers may face challenges and how the Comprehensive Cancer Control Programs (CCCP) can address these needs. Written by Dr. Amari Pearson- Fields, the former Comprehensive Cancer Program Director for Washington DC.

A look at a survivor's survivorship appointment.

Patients with the aggressive blood cancer can turn to immunotherapies like CAR-T cell therapy when disease recurs or becomes resistant.

A heartwarming story reminds one cancer survivor about the good people in the world that sometimes feels overwhelmingly negative.

Treatment for patients with bladder cancer is moving away from VEGF-targeted therapies toward immune checkpoint inhibition, according to one expert.

When people think of caregivers, they often think of adults taking care of their elderly family members, but that is not the reality for many adolescents and young people who are forced into distressful situations when loved ones are diagnosed with cancer.

This time around, newfound joy and passion have added a different layer to Scanxiety.

From the first child born to a patient with cancer from an egg matured in a lab to women with breast cancer taking to the runway for New York Fashion Week, here’s what is making headlines in the cancer space this week.

The Clinical Treatment Act was created to expand clinical trial access to patients insured by Medicaid.

A cancer survivor discusses the ongoing emotional roller coaster ride of cancer survivorship.

A man with breast cancer looks at diet, data and breast density in relation to how he got his cancer.

MK-6482 demonstrated an objective response rate of 24% among patients with advanced clear cell renal cell carcinoma, according to study findings presented at the 2020 Genitourinary Cancers Symposium.

The Food and Drug Administration granted a priority review to the new drug application for lurbinectedin to treat patients with small cell lung cancer.

On every cancer journey we need a strong support group to provide strength, acceptance and love — for one patient with cancer their spouse stepped into that role and beyond.

After five years of follow-up, treatment with Opdivo in those with previously treated advanced or metastatic renal cell carcinoma induced superior survival outcomes.

More than 50% of patients with previously untreated advanced or metastatic renal cell carcinoma were alive at 42 months after being treated with Opdivo plus Yervoy.